Price T Rowe Associates Inc Adaptimmune Therapeutics PLC Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
Shares
1 transactions
Others Institutions Holding ADAP
# of Institutions
83Shares Held
123MCall Options Held
34.2KPut Options Held
16.3K-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$6.3 Million0.69% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR20.5MShares$4.71 Million0.38% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$3.93 Million0.66% of portfolio
-
Two Seas Capital LP Rye, NY14.8MShares$3.41 Million1.31% of portfolio
-
Baillie Gifford & CO11.8MShares$2.72 Million0.01% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $37.6M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...